# US 2024/0116850 A1 · Compositions and methods related to bicyclo[2.2.1] heptanamine-containing compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0116850 A1
- Document ID: US20240116850A1
- Status: Published application
- Kind: A1
- Application number: 18/269,168
- Filed: 2021-12-23
- Published: 2024-04-11
- Earliest claimed: 2020-12-23
- Assignees: The Broad Institute, Inc.; Instituto Carlos Slim De La Salud, A.C.; The Brigham and Women's Hospital, Inc.
- Applicants: The Broad Institute, Inc.; Instituto Carlos Slim de la Salud, A.C.; The Brigham and Women's Hospital, Inc.
- Inventors: Brian T. Chamberlain; Florence F. Wagner; Maria Alimova; Anna Greka
- Web page: https://patentgrep.com/patent/US20240116850A1

## CPC

- C07C 211/38: containing condensed ring systems
- A61P 13/12: of the kidneys
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 201/12: by reactions not involving the formation of nitro groups
- C07C 205/05: having nitro groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C 209/34: by reduction of nitro groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings {in presence of hydrogen-containing gases and a catalyst}
- C07C 209/40: by reduction of hydroxylamino or oxyimino groups
- C07C 209/62: by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds (C07C209/24 takes precedence)
- C07C 211/41: containing condensed ring systems
- C07C 233/06: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C 249/08: by reaction of hydroxylamines with carbonyl compounds
- C07C 269/04: from amines with formation of carbamate groups
- C07C 271/24: with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C 311/20: having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07D 209/48: with oxygen atoms in positions 1 and 3, e.g. phthalimide
- C07D 333/20: by nitrogen atoms (nitro, nitroso radicals C07D333/12)
- C07B 2200/07: Optical isomers
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07C 2601/02: with a three-membered ring
- C07C 2601/04: with a four-membered ring
- C07C 2601/08: the ring being saturated
- C07C 2601/14: The ring being saturated
- C07C 2602/42: the bicyclo ring system containing seven carbon atoms
- C07C 2603/18: Fluorenes; Hydrogenated fluorenes
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present disclosure relates to compositions and methods related to bicyclo[2.2.1]heptanamine-containing compounds and salts thereof.

## Claims

### Claim 1

A compound having a structure represented by formula I:
or a pharmaceutically acceptable salt thereof, wherein
R1 is alkyl, cycloalkyl, aryl, or heteroaryl;
each of R2A, R2B, R2C, and R2D is independently selected from H or alkyl;
R3 are both H or both alkyl;
R4 is H or C(O)OR5 (i.e., to form a carbamate);
R5 is aralkyl or heteroaralkyl;
wherein
the compound is not selected from
or a hydrochloride salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is not a salt of

### Claim 3 (depends on 1, 2)

The compound of claim 1 or 2, wherein the compound has a structure represented by formula Ia, Ib, Ic, or Id:
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein the compound has an enantiomeric excess (ee) or diastereomeric excess (de) greater than 95%, 96%, 97%, 98%, or 99%.

### Claim 5 (depends on 1, 2, 3, 4)

The compound of any one of claims 1-4, wherein the compound is substantially free of one enantiomer and/or of one or more (preferably all) other diastereomers.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The compound of any one of claims 1-5, wherein the compound is a single enantiomer or a single diastereomer.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of claims 1-6, wherein R3 are both H.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of claims 1-6, wherein R4 is H.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of claims 1-6, wherein R1 is alkyl.

### Claim 10 (depends on 9)

The compound of claim 9, wherein R1 is methyl, trifluoromethyl, ethyl, propyl, isopropyl, isobutyl, or tertiary-butyl.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, wherein R1 is cycloalkyl.

### Claim 12 (depends on 11)

The compound of claim 11, wherein R1 is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, wherein R1 is aryl.

### Claim 14 (depends on 13)

The compound of claim 13, wherein R1 is phenyl.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, wherein R1 is heteroaryl.

### Claim 16 (depends on 15)

The compound of claim 15, wherein R1 is thiophenyl.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The compound of any one of claims 1-16, wherein R1 is substituted with alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amide, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamide.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The compound of any one of claims 1-17, wherein R2A is H.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The compound of any one of claims 1-18, wherein R2B is H.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 1-19, wherein R2C is H.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The compound of any one of claims 1-20, wherein R2D is H.

### Claim 22

A compound selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The compound any one of claims 1-22, wherein the salt is a hydrochloride, maleate, phosphate, fumarate, citrate, malate (e.g., L-malate), lactate, succinate, adipate, acetate, tosylate, mesylate, besylate, benzoate, hydrobromide, aspartate (e.g., L-aspartate), glutamate (e.g., L-glutamate), or tartrate (e.g., L-tartrate).

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The compound of any one of claims 1-23, wherein the compound is a maleate, phosphate, fumarate, citrate, malate (e.g., L-malate), lactate, succinate, adipate, acetate, tosylate, mesylate, besylate, benzoate, hydrobromide, aspartate (e.g., L-aspartate), glutamate (e.g., L-glutamate), or tartrate (e.g., L-tartrate) salt.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The compound of any one of claims 1-24, wherein the compound is a maleate, fumarate, succinate, L-malate, or phosphate salt.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The compound of any one of claims 1-25, wherein the compound is a maleate salt.

### Claim 27

A crystalline form of a compound having a structure represented by formula IIa:

### Claim 28 (depends on 27)

The crystalline form of claim 27, wherein the crystalline form has 20 values of about 23.2, about 18.3, about 18.6, about 14.0, about 13.7, about 24.4, about 20.7, or about 18.9.

### Claim 29 (depends on 27)

The crystalline form of claim 27, wherein the crystalline form has 20 values of about 23.2, about 18.3, about 18.6, about 14.0, and about 13.7.

### Claim 30 (depends on 27)

The crystalline form of claim 27, wherein the crystalline form has 20 values of about 23.2, about 18.3, about 18.6, about 14.0, about 13.7, about 24.4, and about 20.7.

### Claim 31 (depends on 27)

The crystalline form of claim 27, wherein the crystalline form has 20 values of about 23.2, about 18.3, and about 18.6, about 14.0, about 13.7, about 24.4, about 20.7, and about 18.9.

### Claim 32 (depends on 27)

The crystalline form of claim 27, wherein the crystalline form has 20 values substantially similar to those recited in Table 22.

### Claim 33 (depends on 27)

The crystalline form of claim 27, wherein the crystalline form has an XRD pattern substantially similar to one of those depicted in FIG. 2A.

### Claim 34

A crystalline form of a compound having a structure represented by formula IIb:

### Claim 35 (depends on 34)

The crystalline form of claim 34, wherein the crystalline form has 20 values of about 22.1, about 19.5, about 23.5, about 27.4, about 33.4, about 11.0, about 21.6, or about 18.5.

### Claim 36 (depends on 34)

The crystalline form of claim 34, wherein the crystalline form has 20 values of about 22.1, about 19.5, about 23.5, about 27.4 and about 33.4.

### Claim 37 (depends on 34)

The crystalline form of claim 34, wherein the crystalline form has 20 values of about 22.1, about 19.5, about 23.5, about 27.4 about 33.4, about 11.0, and about 21.6.

### Claim 38 (depends on 34)

The crystalline form of claim 34, wherein the crystalline form has 20 values of about 22.1, about 19.5, about 23.5, about 27.4, about 33.4, about 11.0, about 21.6, and about 18.5.

### Claim 39 (depends on 34)

The crystalline form of claim 34, wherein the crystalline form has 20 values substantially similar to those recited in Table 26.

### Claim 40 (depends on 34)

The crystalline form of claim 34, wherein the crystalline form has an XRD pattern substantially similar to that depicted in FIG. 2C.

### Claim 41

A crystalline form of a compound having a structure represented by formula IIc:

### Claim 42 (depends on 41)

The crystalline form of claim 41, wherein the crystalline form has 20 values of about 19.5, about 21.8, about 14.4, about 10.9, about 19.2, about 14.8, about 27.3, or about 22.1.

### Claim 43 (depends on 41)

The crystalline form of claim 41, wherein the crystalline form has 20 values of about 19.5, about 21.8, about 14.4, about 10.9, and about 19.2.

### Claim 44 (depends on 41)

The crystalline form of claim 41, wherein the crystalline form has 20 values of about 19.5, about 21.8, about 14.4, about 10.9, about 19.2, about 14.8, or about 27.3.

### Claim 45 (depends on 41)

The crystalline form of claim 41, wherein the crystalline form has 20 values of about 19.5, about 21.8, about 14.4, about 10.9, about 19.2, about 14.8, about 27.3, and about 22.1.

### Claim 46 (depends on 41)

The crystalline form of claim 41, wherein the crystalline form has 20 values substantially similar to those recited in Table 31.

### Claim 47 (depends on 41)

The crystalline form of claim 41, wherein the crystalline form has an XRD pattern substantially similar to that depicted in FIG. 2G.

### Claim 48

A crystalline form of a compound having a structure represented by formula IId:

### Claim 49 (depends on 48)

The crystalline form of claim 48, wherein the crystalline form has 20 values of about 7.7, about 23.1, about 16.1, about 14.4, about 21.8, about 24.7, about 17.5, or about 12.4.

### Claim 50 (depends on 48)

The crystalline form of claim 48, wherein the crystalline form has 20 values of about 7.7, about 23.1, about 16.1, about 14.4, and about 21.8.

### Claim 51 (depends on 48)

The crystalline form of claim 48, wherein the crystalline form has 20 values of about 7.7, about 23.1, about 16.1, about 14.4, about 21.8, about 24.7, and about 17.5.

### Claim 52 (depends on 48)

The crystalline form of claim 48, wherein the crystalline form has 20 values of about 7.7, about 23.1, about 16.1, about 14.4, about 21.8, about 24.7, about 17.5, and about 12.4.

### Claim 53 (depends on 48)

The crystalline form of claim 48, wherein the crystalline form has 20 values substantially similar to those recited in Table 29.

### Claim 54 (depends on 48)

The crystalline form of claim 48, wherein the crystalline form has an XRD pattern substantially similar to that depicted in FIG. 2E.

### Claim 55

A crystalline form of a compound having a structure represented by formula IIe:

### Claim 56 (depends on 55)

The crystalline form of claim 55, wherein the crystalline form has 20 values of about 6.9, about 20.8, about 17.1, about 17.4, about 23.9, about 19.6, about 13.6, or about 19.9.

### Claim 57 (depends on 55)

The crystalline form of claim 55, wherein the crystalline form has 20 values of about 6.9, about 20.8, about 17.1, about 17.4, and about 23.9.

### Claim 58 (depends on 55)

The crystalline form of claim 55, wherein the crystalline form has 20 values of about 6.9, about 20.8, about 17.1, about 17.4, and about 23.9, about 19.6, and about 13.6.

### Claim 59 (depends on 55)

The crystalline form of claim 55, wherein the crystalline form has 20 values of about 6.9, about 20.8, about 17.1, about 17.4, about 23.9, about 19.6, about 13.6, and about 19.9.

### Claim 60 (depends on 55)

The crystalline form of claim 55, wherein the crystalline form has 20 values substantially similar to those recited in Table 25.

### Claim 61 (depends on 55)

The crystalline form of claim 55, wherein the crystalline form has an XRD pattern substantially similar to that depicted in FIG. 2B.

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

A pharmaceutical composition comprising a compound or crystalline form of any one of claims 1-61 wherein R4 is H and a pharmaceutically acceptable excipient.

### Claim 63

A method of making a compound represented by formula V according to Scheme I:
wherein
R1 is alkyl, cycloalkyl, aryl, or heteroaryl;
each of R2A, R2B, R2C, and R2D is independently selected from H or alkyl;
R3 are both H or both alkyl; and
the solvent is an aromatic solvent, a heteroaromatic solvent, an organic acid, an alcohol, halogenated alcohol, an ether, a nitrile, a formamide, alkylamine, or a protic polar solvent.

### Claim 64 (depends on 63)

The method of claim 63, wherein the method is represented by Scheme Ia:

### Claim 65 (depends on 63)

The method of claim 63, wherein the method is represented by Scheme Ib:

### Claim 66 (depends on 63)

The method of claim 63, wherein the method is represented by Scheme Ic:

### Claim 67 (depends on 63)

The method of claim 63, wherein the method is represented by Scheme Id:

### Claim 68 (depends on 63, 64, 65, 66, 67)

The method of any one of claims 63-67, wherein the solvent is an aromatic solvent.

### Claim 69 (depends on 68)

The method of claim 68, wherein the aromatic solvent is toluene.

### Claim 70 (depends on 63, 64, 65, 66, 67)

The method of any one of claims 63-67, wherein the solvent is a heteroaromatic solvent.

### Claim 71 (depends on 70)

The method of claim 70, wherein the heteroaromatic solvent is pyridine.

### Claim 72 (depends on 63, 64, 65, 66, 67)

The method of any one of claims 63-67, wherein the solvent is an organic acid.

### Claim 73 (depends on 72)

The method of claim 72, wherein the organic acid is acetic acid, trifluoroacetic acid, butyric acid, tertiary butyric acid, toluenesulfonic acid, or benzoic acid.

### Claim 74 (depends on 63, 64, 65, 66, 67)

The method of any one of claims 63-67, wherein the solvent is an alcohol.

### Claim 75 (depends on 74)

The method of claim 74, wherein the alcohol is methanol, ethanol, or isopropanol.

### Claim 76 (depends on 63, 64, 65, 66, 67)

The method of any one of claims 63-67, wherein the solvent is a halogenated alcohol.

### Claim 77 (depends on 76)

The method of claim 76, wherein the halogenated alcohol is a fluorinated alcohol.

### Claim 78 (depends on 76, 77)

The method of claim 76 or 77, wherein the halogenated alcohol is difluoroethanol or hexafluoroisopropanol.

### Claim 79 (depends on 63, 64, 65, 66, 67)

The method of any one of claims 63-67, wherein the solvent is an ether.

### Claim 80 (depends on 79)

The method of claim 79, wherein the ether is tetrahydrofuran.

### Claim 81 (depends on 63, 64, 65, 66, 67)

The method of any one of claims 63-67, wherein the solvent is a nitrile.

### Claim 82 (depends on 81)

The method of claim 81, wherein the nitrile is acetonitrile.

### Claim 83 (depends on 63, 64, 65, 66, 67)

The method of any one of claims 63-67, wherein the solvent is a formamide.

### Claim 84 (depends on 83)

The method of claim 83, wherein the formamide is dimethyl formamide.

### Claim 85 (depends on 63, 64, 65, 66, 67)

The method of any one of claims 63-67, wherein the solvent is an alkylamine.

### Claim 86 (depends on 85)

The method of claim 85, wherein the alkylamine is diethylamine, trimethylamine, or 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU).

### Claim 87 (depends on 63, 64, 65, 66, 67)

The method of any one of claims 63-67, wherein the solvent is a protic polar solvent.

### Claim 88 (depends on 87)

The method of claim 87, wherein the protic polar solvent is water.

### Claim 89 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88)

The method of any one of claims 63-88, wherein the solvent further comprises an additive.

### Claim 90 (depends on 89)

The method of claim 89, wherein the additive is an organic acid.

### Claim 91 (depends on 90)

The method of claim 90, wherein the organic acid is acetic acid.

### Claim 92 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91)

The method of any one of claims 63-91, wherein the method is performed in a temperature range from 20° C. to 100° C.

### Claim 93 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92)

The method of any one of claims 63-92, wherein the method is performed at about 30° C., about 35° C., about 40° C., about 45° C., or about 50° C.

### Claim 94 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93)

The method of any one of claims 63-93, wherein the method is performed at about 40° C.

### Claim 95 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94)

The method of any one of claims 63-94, wherein the method is performed for 24 to 144 hours.

### Claim 96 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

The method of any one of claims 63-95, wherein the method is performed for between 48 to 96 hours.

### Claim 97 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The method of any one of claims 63-96, wherein the method is performed for about 72 hours.

### Claim 98 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97)

The method of any one of claims 63-97, wherein the method further comprises a step represented by Scheme II:
wherein
X− is an organic or inorganic anion;
the catalyst is a noble metal oxide (e.g., platinum oxide), a nickel-aluminum alloy (e.g., Raney nickel), or a noble metal on carbon (e.g., palladium on carbon); and
the acid is a Brønsted acid.

### Claim 99 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97)

The method of any one of claims 63-97, wherein the method further comprises a step represented by Scheme IIa:
wherein
X− is an organic or inorganic anion;
the catalyst is a noble metal oxide (e.g., platinum oxide), a nickel-aluminum alloy (e.g., Raney nickel), or a noble metal on carbon (e.g., palladium on carbon); and
the acid is a Brønsted acid.

### Claim 100 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97)

The method of any one of claims 63-97, wherein the method further comprises a step represented by Scheme IIb:
wherein
X− is an organic or inorganic anion;
the catalyst is a noble metal oxide (e.g., platinum oxide), a nickel-aluminum alloy (e.g., Raney nickel), or a noble metal on carbon (e.g., palladium on carbon); and
the acid is a Brønsted acid.

### Claim 101 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97)

The method of any one of claims 63-97, wherein the method further comprises a step represented by Scheme IIc:
wherein
X− is an organic or inorganic anion;
the catalyst is a noble metal oxide (e.g., platinum oxide), a nickel-aluminum alloy (e.g., Raney nickel), or a noble metal on carbon (e.g., palladium on carbon); and
the acid is a Brønsted acid.

### Claim 102 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97)

The method of any one of claims 63-97, wherein the method further comprises a step represented by Scheme IId:
wherein
X− is an organic or inorganic anion;
the catalyst is a noble metal oxide (e.g., platinum oxide), a nickel-aluminum alloy (e.g., Raney nickel), or a noble metal on carbon (e.g., palladium on carbon); and
the acid is a Brønsted acid.

### Claim 103 (depends on 98, 99, 100, 101, 102)

The method of any one of claims 98-102, wherein the catalyst is palladium on carbon.

### Claim 104 (depends on 98, 99, 100, 101, 102)

The method of any one of claims 98-102, wherein the acid is a hydrogen halide.

### Claim 105 (depends on 98, 99, 100, 101, 102, 103, 104)

The method of any one of claims 98-104, wherein the acid is HCl (e.g., HCl in ethyl acetate or diethylether).

### Claim 106 (depends on 100, 101, 102)

The method of any one of claims 100-102, wherein the acid is maleic acid.

### Claim 107

A method of making a compound represented by formula VV according to Scheme III:
wherein
R1 is alkyl, cycloalkyl, aryl, or heteroaryl;
each of R2A, R2B, R2C, and R2D is independently selected from H or alkyl;
R3 are both H or both alkyl; and
X is an inorganic anion (e.g., chloride); and
the base is an inorganic base (e.g., sodium acetate).

### Claim 108 (depends on 107)

The method of claim 107, wherein the method is represented by Scheme IIIa:

### Claim 109 (depends on 107)

The method of claim 107, wherein the method is represented by Scheme IIIb:

### Claim 110

A method of making a compound represented by formula VI according to Scheme IV:
wherein
R1 is alkyl, cycloalkyl, aryl, or heteroaryl;
each of R2A, R2B, R2C, and R2D is independently selected from H or alkyl;
R3 are both H or both alkyl; and
X− is an organic or inorganic anion;
the catalyst is a noble metal oxide (e.g., platinum oxide); and
the acid is a Brønsted acid (e.g., acetic acid).

### Claim 111 (depends on 110)

The method of claim 110, wherein the method is represented by Scheme IVa:

### Claim 112 (depends on 110)

The method of claim 110, wherein the method is represented by Scheme IVb:

### Claim 113 (depends on 110)

The method of claim 110, wherein the method is represented by Scheme IVc:

### Claim 114 (depends on 110)

The method of claim 110, wherein the method is represented by Scheme IVd:

### Claim 115 (depends on 110, 111, 112, 113, 114)

The method of any one of claims 110-114, wherein the catalyst is platinum oxide.

### Claim 116 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115)

The method of any one of claims 63-115, wherein the compound has an enantiomeric excess (ee) greater than 95%, 96%, 97%, 98%, or 99%.

### Claim 117 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116)

The method of any one of claims 63-116, wherein the compound is substantially free of one enantiomer and/or of one or more (preferably all) other diastereomers.

### Claim 118 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117)

The method of any one of claims 63-117, wherein the compound is a single enantiomer or a single diastereomer.

### Claim 119 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118)

The method of any one of claims 63-118, wherein R1 is alkyl.

### Claim 120 (depends on 119)

The method of claim 119, wherein R1 is methyl, trifluoromethyl, ethyl, propyl, isopropyl, isobutyl, or tertiary-butyl.

### Claim 121 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118)

The method of any one of claims 63-118, wherein R1 is cycloalkyl.

### Claim 122 (depends on 121)

The method of claim 121, wherein R1 is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

### Claim 123 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118)

The method of any one of claims 63-118, wherein R1 is aryl.

### Claim 124 (depends on 123)

The method of claim 123, wherein R1 is phenyl.

### Claim 125 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118)

The method of any one of claims 63-118, wherein R1 is heteroaryl.

### Claim 126 (depends on 125)

The method of claim 125, wherein R1 is thiophenyl.

### Claim 127 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126)

The method of any one of claims 63-126, wherein R1 is substituted with alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amide, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamide.

### Claim 128 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127)

The method of any one of claims 63-127, wherein R2A is H.

### Claim 129 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128)

The method of any one of claims 63-128, wherein R2B is H.

### Claim 130 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129)

The method of any one of claims 63-129, wherein R2C is H.

### Claim 131 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130)

The method of any one of claims 63-130, wherein R2D is H.

### Claim 132 (depends on 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131)

The method of any one of claims 98-131, wherein the compound is represented by formula VI is a salt of a compound selected from
or a pharmaceutically acceptable salt thereof.

### Claim 133 (depends on 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132)

The method of any one of claims 98-132, wherein X− is chloride, acetate, maleate, phosphate, fumarate, citrate, malate (e.g., L-malate), lactate, succinate, adipate, acetate, tosylate, mesylate, besylate, benzoate, hydrobromide, aspartate (e.g., L-aspartate), glutamate (e.g., L-glutamate), or tartrate (e.g., L-tartrate).

### Claim 134 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133)

The method of any one of claims 63-133, wherein the method further comprises a step represented by Scheme V:
wherein
Z is halo;
R5 is aralkyl or heteroaralkyl;
Base is a carbonate base or a nitrogenous base.

### Claim 135 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133)

The method of any one of claims 63-133, wherein the method further comprises a step represented by Scheme Va:
wherein
Z is halo;
R5 is aralkyl or heteroaralkyl;
Base is a carbonate base or a nitrogenous base.

### Claim 136 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133)

The method of any one of claims 63-133, wherein the method further comprises a step represented by Scheme Vb:
wherein
Z is halo;
R5 is aralkyl or heteroaralkyl;
Base is a carbonate base or a nitrogenous base.

### Claim 137 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133)

The method of any one of claims 63-133, wherein the method further comprises a step represented by Scheme Vc:
wherein
Z is halo;
R5 is aralkyl or heteroaralkyl;
Base is a carbonate base or a nitrogenous base.

### Claim 138 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133)

The method of any one of claims 63-133, wherein the method further comprises a step represented by Scheme Vd:
wherein
Z is halo;
R5 is aralkyl or heteroaralkyl;
Base is a carbonate base or a nitrogenous base.

### Claim 139 (depends on 134, 135, 136, 137, 138)

The method of any one of claims 134-138, wherein Z is chloro.

### Claim 140 (depends on 134, 135, 136, 137, 138, 139)

The method of any one of claims 134-139, wherein R3 is aralkyl.

### Claim 141 (depends on 134, 135, 136, 137, 138, 139, 140)

The method of any one of claims 134-140, wherein R3 is benzyl.

### Claim 142 (depends on 134, 135, 136, 137, 138, 139, 140, 141)

The method of any one of claims 134-141, wherein R3 is substituted with alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amide, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamide.

### Claim 143 (depends on 134, 135, 136, 137, 138, 139, 140, 141, 142)

The method of any one of claims 134-142, wherein R3 is substituted with nitro.

### Claim 144 (depends on 134, 135, 136, 137, 138, 139, 140, 141, 142, 143)

The method of any one of claims 134-143, wherein R3 is substituted with nitro at the para-position.

### Claim 145 (depends on 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144)

The method of any one of claims 134-144, wherein the nitrogenous base is a secondary or tertiary alkylamine (e.g., trimethylamine or diisopropylamine).

### Claim 146 (depends on 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144)

The method of any one of claims 134-144, wherein the carbonate base is sodium carbonate, potassium carbonate, calcium carbonate, or cesium carbonate.

### Claim 147 (depends on 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146)

The method of any one of claims 134-146, wherein the carbonate base is sodium carbonate.

### Claim 148 (depends on 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146)

The method of any one of claims 134-146, wherein the method further comprises a solvent.

### Claim 149 (depends on 148)

The method of claim 148, wherein the solvent is a mixture of water and a halogenated solvent.

### Claim 150 (depends on 149)

The method of claim 149, wherein the halogenated solvent is dichloromethane.

### Claim 151 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

A method of treating or preventing a toxic proteinopathy with a compound, crystalline form or pharmaceutical composition of any one of claims 1-62; wherein R4 is H.

### Claim 152 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

A method for selecting a treatment for a toxic proteinopathy resulting from mutant protein accumulation in the early secretory pathway in a subject in need thereof, the method comprising:
(a) identifying a subject as having or being at risk of developing a toxic proteinopathy resulting from mutant protein accumulation in the early secretory pathway; and
(b) selecting a compound, crystalline form or pharmaceutical composition of any one of claims 1-62 wherein R4 is H as a treatment for the subject identified as having or being at risk of developing a toxic proteinopathy resulting from mutant protein accumulation in the early secretory pathway.

### Claim 153 (depends on 151, 152)

The method of claim 151 or 152, wherein the toxic proteinopathy is selected from a neurodegenerative disease, MUC1-associated kidney disease, autosomal dominant kidney disease caused by uromodulin mutations, and a form of retinitis pigmentosa (RP) caused by a rhodopsin mutation.

### Claim 154 (depends on 153)

The method of claim 153, wherein the toxic proteinopathy is MUC1-associated kidney disease.

### Claim 155 (depends on 152, 153, 154)

The method of any one of claims 152-154, wherein the subject has one or more of the following: end-stage renal disease, urinalysis revealing minimal protein and no blood, slowly progressive kidney failure, hyperglycemia and/or gout.

### Claim 156 (depends on 152, 153, 154, 155)

The method of any one of claims 152-155, wherein the subject has been identified to be in need of dialysis or kidney transplantation.

### Claim 157 (depends on 152, 153)

The method of claim 152 or 153, wherein the subject has one or more of the following symptoms of RP: night blindness; tunnel vision (due to loss of peripheral vision); latticework vision; photopsia (blinking/shimmering lights); photophobia (aversion to bright lights); development of bone spicules in the fundus; slow adjustment from dark to light environments and vice versa; blurring of vision; poor color separation; loss of central vision; and/or blindness.

### Claim 158 (depends on 152, 155, 156)

The method of any one of claims 152, 155 or 156, wherein step (b) comprises identifying the presence in the subject of a mutation in MUC1, UMOD and/or rhodopsin, optionally wherein the MUC1 mutation is a MUC1 frameshift mutation, the UMOD mutation is a C126R UMOD mutation and/or the rhodopsin mutation is a P23H rhodopsin mutation.

### Claim 159 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 152, 153, 154, 155, 156, 157, 158)

The method of any one of claims 152-158, further comprising: (c) administering the selected compound, crystalline form or pharmaceutical composition of any one of claims 1-62 wherein R4 is H to the subject.

### Claim 160 (depends on 152, 153, 154, 155, 156, 157, 158, 159)

The method of any one of claims 152-159, wherein the subject is human.

### Claim 161 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

A method for treating or preventing a proteinopathy resulting from mutant protein accumulation in the early secretory pathway in a subject, the method comprising:
identifying a subject as having or at risk of developing a proteinopathy resulting from mutant protein accumulation in the early secretory pathway in a subject; and
administering a compound, crystalline form or pharmaceutical composition of any one of claims 1-62 wherein R4 is H to the subject in an amount sufficient to cause reduction or improvement of a symptom of the proteinopathy resulting from mutant protein accumulation in the early secretory pathway in the subject,
thereby treating or preventing the proteinopathy resulting from mutant protein accumulation in the early secretory pathway in the subject.

### Claim 162 (depends on 161)

The method of claim 161, wherein said compound causes release of MUC1, UMOD and/or rhodopsin from the early secretory compartment, optionally wherein said compound causes release of MUC1, UMOD and/or rhodopsin from the endoplasmic reticulum (ER), from COPI-coated vesicles, from COPII-coated vesicles and/or from the Golgi apparatus.

### Claim 163 (depends on 161, 162)

The method of claim 161 or 162, wherein the proteinopathy is selected from a neurodegenerative disease, MUC1-associated kidney disease, autosomal dominant kidney disease caused by uromodulin mutations, a form of retinitis pigmentosa (RP) caused by a rhodopsin mutation, pulmonary alveolar proteinosis or ApoL1-positive kidney disease, and type II diabetes, optionally wherein the neurodegenerative disease is selected from Alzheimer's disease (AD) and other dementias; Parkinson's disease (PD) and PD-related disorders; lysozyme amyloidosis; dialysis amyloidosis; cystic fibrosis; cataracts; odontogenic tumor amyloid; familial British dementia; hereditary cerebral hemorrhage with amyloidosis (Icelandic); familial amyloidotic neuropathy or senile systemic/cardiomyopathy; ApoAII amyloidosis; familial amyloidosis of the Finnish type (FAF); fibrinogen amyloidosis; inclusion body myositis/myopathy; hereditary lattice corneal dystrophy; prion disease (including, e.g., Creutzfeldt-Jakob Disease, variant Creutzfeldt-Jakob Disease, Bovine Spongiform Encephalopathy (BSE), Kuru, Gerstmann-Straussler-Scheinker disease, fatal familial insomnia (FFI), scrapie, and other animal TSEs); motor neuron diseases (MND; including, e.g., Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS), Progressive Bulbar Palsy (PBP), Pseudobulbar Palsy, Progressive Muscular Δtrophy, Spinal Muscular Δtrophy (Type 1, Type 2, Type 3, Type 4), and Kennedy's Disease); and spinocerebellar ataxia (SCA).

### Claim 164 (depends on 163)

The method of claim 163, wherein the proteinopathy is MUC1-associated kidney disease.

### Claim 165 (depends on 161, 162, 163, 164)

The method of any one of claims 161-164, wherein the symptom of the proteinopathy is selected from end-stage renal disease, urinalysis revealing minimal protein and no blood, slowly progressive kidney failure, hyperglycemia, gout, a need for dialysis or kidney transplantation, night blindness; tunnel vision (optionally due to loss of peripheral vision); latticework vision; photopsia (blinking/shimmering lights); photophobia (aversion to bright lights); development of bone spicules in the fundus; slow adjustment from dark to light environments and vice versa; blurring of vision; poor color separation; loss of central vision; and/or blindness.

### Claim 166 (depends on 161, 162, 163, 164, 165)

The method of any one of claims 161-165, wherein the subject has a mutation in MUC1, UMOD and/or rhodopsin, optionally wherein the MUC1 mutation is a MUC1 frameshift mutation, the UMOD mutation is a C126R UMOD mutation and/or the rhodopsin mutation is a P23H rhodopsin mutation.

### Claim 167 (depends on 66, 161, 162, 163, 164, 165, 166)

The method of any one of claims 161-166, wherein the pharmaceutical composition comprising a compound of claim 66 wherein R4 is H is administered to the subject via the oral route (P.O.).

### Claim 168 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 161, 162, 163, 164, 165, 166)

The method of any one of claims 161-166, wherein the compound or crystalline form of any one of claims 1-65 wherein R4 is H comprises a pharmaceutically-acceptable carrier/excipient.

### Claim 169 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

A method for reducing or eliminating accumulation of a mutant protein in the ER lumen of a cell, in COPI and/or COPII vesicles of a cell, in the cis-Golgi lumen of a cell, in the medial cisternae of the Golgi of a cell, and/or in the trans-Golgi network (TGN) of a cell, the method comprising administering a compound, crystalline form or pharmaceutical composition of any one of claims 1-66 wherein R4 is H to the environment of a cell in an amount sufficient to reduce or eliminate accumulation of the mutant protein in the ER lumen of the cell, in COPI and/or COPII vesicles of the cell, in the cis-Golgi lumen of the cell, in the medial cisternae of the Golgi of the cell, and/or in the trans-Golgi network (TGN) of the cell, thereby reducing or eliminating accumulation of the mutant protein in the ER lumen of the cell, in COPI and/or COPII vesicles of the cell, in the cis-Golgi lumen of the cell, in the medial cisternae of the Golgi of the cell, and/or in the trans-Golgi network (TGN) of the cell.

### Claim 170 (depends on 169)

The method of claim 169, wherein the mutant protein is selected from a MUC1 frameshift mutant protein, a UMOD pathogenic variant and a rhodopsin mutant, optionally wherein the MUC1 mutation is a MUC1 frameshift mutation, the UMOD mutation is a C126R UMOD mutation and/or the rhodopsin mutation is a P23H rhodopsin mutation.

### Claim 171 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

A pharmaceutical composition for treating a subject having or at risk of developing a proteinopathy comprising a therapeutically effective amount of a compound or crystalline form of any one of claims 1-61 wherein R4 is H and a pharmaceutically acceptable carrier.

### Claim 172 (depends on 171)

The pharmaceutical composition of claim 171, wherein the proteinopathy is selected from a neurodegenerative disease, MUC1-associated kidney disease, autosomal dominant kidney disease caused by uromodulin mutations and a form of retinitis pigmentosa (RP) caused by a rhodopsin mutation.

### Claim 173 (depends on 171, 172)

The pharmaceutical composition of claim 171 or claim 172, wherein the subject is human.

### Claim 174 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

A method of treating or preventing MUC1-associated kidney disease (MKD) in a subject in need thereof, the method comprising administering to the subject a compound, crystalline form or pharmaceutical composition of any one of claims 1-62 wherein R4 is H as a first agent and a second agent selected from vitamin D, a phosphate binder, a blood pressure medication and a diuretic, thereby treating or preventing MKD in the subject.
